IgTT-1E

N/A

Report date: 2023/07/19 17:49:14

Base Information

Drug NameIgTT-1E

Drug Alias NameBispecific IgTT 1E antibodiesIgTT-1EIgTT-1-E

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsProgrammed death-ligand 1 blockers

TargetsProgrammed death-ligand 1Epidermal growth factor receptor erbB1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySpain

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLeadartis SL

China Registration ClassN/A

Develop Information

Active CompaniesLeadartis SL

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A